Bcl‐2/Bcl‐xL inhibition predominantly synergistically enhances the anti‐neoplastic activity of a low‐dose CUSP9 repurposed drug regime against glioblastoma

BACKGROUND AND PURPOSE: Drug repurposing represents a promising approach to safely accelerate the clinical application of therapeutics with anti‐cancer activity. In this study, we examined whether inhibition of the anti‐apoptotic Bcl‐2 family proteins Bcl‐2 and Bcl‐xL enhances the biological effects...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Pharmacol
Main Authors: Halatsch, Marc‐Eric, Kast, Richard Eric, Dwucet, Annika, Hlavac, Michal, Heiland, Tim, Westhoff, Mike‐Andrew, Debatin, Klaus‐Michael, Wirtz, Christian Rainer, Siegelin, Markus David, Karpel‐Massler, Georg
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2019
Assuntos:
Research Papers
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6715605/
https://ncbi.nlm.nih.gov/pubmed/31222722
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bph.14773
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados